Who to call at IMMIX BIOPHARMA, INC., and when
Fundz watches for the moments IMMIX BIOPHARMA, INC. starts buying, and tells you who to reach.
- An alert the day IMMIX BIOPHARMA, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at IMMIX BIOPHARMA, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at IMMIX BIOPHARMA, INC.. With Fundz connected, it knows.
IMMIX BIOPHARMA, INC.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
immixbio.comAI Executive Summary
AI-powered analysis of 8-K filing content
Immix Biopharma announced that NXC-201 achieved an 89% complete response rate in a Phase 2 clinical trial for relapsed/refractory light chain amyloidosis, representing significant progress in their drug development pipeline that could positively impact market position and investor sentiment.
Key Takeaways
NXC-201 demonstrated an 89% complete response rate in 45 patients with relapsed/refractory AL amyloidosis in the Phase 2 NEXICART-2 trial
This clinical milestone represents substantial advancement in Immix Biopharma's research and development efforts
2 more takeaways
Related Filings (1)
1 more filing from IMMIX BIOPHARMA, INC. in the last 90 days
Filing Overview
What This Means
IMMIX BIOPHARMA, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.